Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes

Sponsor
Canadian Cancer Trials Group
Study ID
NCT06439225
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Docetaxel — DRUG
    75mg/m2 q21 days
  • Carboplatin — DRUG
    AUC5 q21 days

Study Details

The usual approach for most patients who are not in a study is treatment with docetaxel. This study is being done to answer the following question: Can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual approach? This study is being done to find out if this approach is better or worse than the usual approach for prostate cancer. The usual approach is defined as the care most people get for prostate cancer.

Key Dates

First listed
Jun 3, 2024
Start date
Dec 30, 2024
Status verified
Apr 2026
Primary completion
Sep 30, 2029
Completion
Mar 31, 2030

Study Design

Enrollment
236 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Docetaxel
  • Experimental: Carboplatin + Docetaxel

Primary Outcome Measure

Overall Survival [ Time Frame: 5.25 years ]

Central Contacts

Find similar trials

Nationwide
Prostate cancer trialsOncology trialsProstate oncology trialsMen's health trialsUrology trials

Related Studies